Fibrinolytic components after venous occlusion and concentrations of tissue plasminogen activator
Introduction
In the complex pathogenesis of venous thrombosis one important factor promoting the development of venous thrombosis is a defective fibrinolytic system. This system is activated by various agents, an important one being the tissue type plasminogen activator, localised to the vessel wall. It is well known that many patients with recurrent idiopathic venous thrombosis have defective fibrinolytic systems-that is, decreased vessel wall fibrinolysis or defective release of activators after venous occlusion tests, or both.' 8 The role of fibrinolytic inhibitors in association with venous thrombosis was first described in 1961. 9 Since then several studies have dealt with different inhibitors and their role in the disease.
A new rapid inhibitor to tissue plasminogen activator has been identified,'0 -3 but its physiological importance in patients with thrombosis is less well understood. We aimed therefore to study both the fibrinolytic components in postocclusion plasma and the tissue plasminogen activator inhibitor in patients with recurrent deep venous thrombosis.
Subjects and methods
We studied 60 men and 40 women, aged (mean 43) years, who had been referred because of recurrent deep venous thrombosis or pulmonary embolism without any other known diseases. All the patients were investigated at least three months after their latest thrombotic episode. Diagnosis was always verified by phlebography or pulmonary scintigraphy and angiography. At the time of investigation 73 of the patients were taking vitamin K antagonists.
Fifty seven volunteers (policemen, doctors, nurses, office workers, mechanics, and technicians) aged 20-60 (mean 33) years, of whom 27 were women, served as controls. All were apparently healthy, and none had any history of superficial thrombophlebitis, deep venous thrombosis, or any other disease in which thrombosis is commonly a complicating factor. None of the female controls was taking a contraceptive drug. Controls and patients were studied in parallel.
COLLECTION OF BLOOD Citrated, platelet poor plasma was prepared as previously described.'4 For the fibrin plate assay the plasma samples were not frozen but tested immediately, other samples being stored at -80°C until use. The samples for assay of tissue plasminogen activator by chromogenic substrate were kept on ice, centrifuged at 0C without delay, and frozen rapidly. For immunoradiometric measurement of tissue plasminogen activator blood was collected in edetic acid (0 38 mol/l (11 g/100 ml)) at a ratio of nine to one.
VENOUS OCCLUSION TEST
Venous occlusion was achieved by applying a sphygmomanometer cuff around each arm and inflating the cuffs to maintain a pressure midway between the systolic and diastolic pressures for 20 minutes. '5 Blood samples for measuring the released plasminogen activators were drawn, from an antecubital vein, immediately before the cuffs were applied and again immediately before they were deflated. The mean increase in plasminogen activators in the samples from each arm was calculated.
COAGULATION AND FIBRINOLYTIC STUDIES
The following variables were determined: platelet count; automated activated partial thromboplastin time (APTT; General Diagnostics, New Jersey); one stage prothrombin time; prothrombin, factor VII, and factor X concentrations (Owren's method); factor V concentration; fibrinogen concentration; thrombin time; reptilase time; factor VIII clotting activity; and factor VIII related antigen. The methods have been described elsewhere.'4 16 Plasminogen was measured both by radioimmunodiffusion (own antiserum) and amidolytically with S-2251 (KabiVitrum AB; Sweden).'7 Antithrombin III was assayed by electroimmunoassay"I and amidolytically with S-2238 (KabiVitrum AB, Sweden).19 r2 Antiplasmin was assayed amidolytically with S-2251." Protein C was assayed by a semiquantitative immunochemical method2l with own antiserum.
DETERMINATION OF PLASMINOGEN ACTIVATORS
The plasminogen activators released during venous occlusion were studied using three different methods. As standard for the assays we used human tissue plasminogen activator (NIBSC reagent 83/517), and results were expressed as U/ml.
(1) The fibrin plate method22-Plasminogen rich human fibrinogen (KabiVitrum AB; Stockholm) was used. Undiluted citrated plasma was deposited directly on the fibrin plates in aliquots of 0 03 ml in triplicate, and the plates were incubated at 37 C for 20 hours. The lytic zones were recorded as follows: two perpendicular diameters of the lysed areas were measured (mm), the readings multiplied by each other, and the square root calculated.
(2) Tissue plasminogen activator (S-2251)-Tissue plasminogen activator was measured amidolytically according to the method of Gyzander et al. 23 The tissue plasminogen activator and plasminogen in the sample were adsorbed to lysine sepharose. The lysine sepharose was then mixed with glu-plasminogen, poly-D-lysine, and S-2251, and the absorbance was read.
(3) Tissue plasminogen activator antigen-Tissue plasminogen activator substance was analysed by immunoradiometric assay as described by Holmberg et al. 24 Purified antibodies to melanoma activator were prepared as described by Wallen et al25 and radiolabelled with iodine-125 by the lactoperoxidase method. The assay was performed as a two side phase assay in polystyrene tubes.
MEASUREMENT OF TISSUE PLASMINOGEN ACTIVATOR INHIBITORS
The rapid tissue plasminogen activator inhibitor was measured by adding 10 ng purified melanoma activator (LBK 66; KabiVitrum AB, Sweden: 1 ng contains 1 U tissue plasminogen activator) per ml plasma in various dilutions (1:1, 1:2, 1:5, 1:10, and 1:20). After incubation for 15 minutes at 37°C residual activator activity was measured with S-225 1 as described above. Inhibitor activity was expressed in units, one inhibitor unit being defined as the amount required to neutralise 1 U tissue plasminogen activator. The tissue plasminogen activator inhibitor was always determined in samples taken before venous occlusion.
STATISTICAL METHODS
The Mann-Whitney rank sum test for unpaired observations was used to assess significance of difference, the level of significance chosen being p < 0 05.
Results
All patients had normal platelet counts, activated partial thromboplastin times, one stage prothrombin times, factor V concentrations, factor VIII clotting activities, factor VIII related antigen concentrations, thrombin times, reptilase times, plasminogen concentrations, antithrombin III concentrations, ax antiplasmin concentrations, and protein C concentrations.
The In the present study of 100 consecutive patients with recurrent deep venous thrombosis or pulmonary embolism, or both, the fibrinolytic response after 20 minutes of venous occlusion was decreased in 33, a somewhat lower incidence than in our earlier studies.' 41 That the mean age of our control group was 10 years lower than that of th; thrombotic patients was probably immaterial as no clear relation has been shown between age and ?ibrinolysis.' None of the patients had any abnormalities in concentrations of antithrombin III or protein C, two factors known to predispose to venous thrombosis.13 44 Interestingly, two different mechanisms responsible for the poor fibrinolytic response could be distinguished. After venous occlusion one group of the poor responders (11 patients The role of platelets in the pathogenesis of vasculitis and the formation of coronary artery aneurysms was studied in 19 children with Kawasaki disease and five with polyarteritis. All patients with Kawasaki disease developed thrombocytosis in the third week of illness. The peak platelet count was significantly correlated (p <0 005) with the subsequent development of coronary artery aneurysms. The rise in platelet count was associated with the appearance in the circulation of a factor that induced aggregation and serotonin release in normal platelets. This factor was shown to be of high molecular weight, and its activity was lost at low pHfeatures suggestive of an immune complex. Immune complexes, detected by precipitation with polyethylene glycol, also appeared in the circulation as the platelet count increased. These complexes induced platelet aggregation, and there was a significant correlation (p <0 001) between the concentrations of IgG and IgA in the polyethylene glycol precipitated material and the platelet aggregating activity. Similar activity was also detected in patients with polyarteritis but followed a different time course, persisting in the circulation for several months in association with continued disease activity. These findings imply that different mechanisms have a role in distinct phases of Kawasaki disease. The initial feverish phase (probably infective) is probably followed by an immune complex vasculitis that occurs when antibodies to the initiating agent appear in the circulation. The immune complexes aggregate platelets and induce release of serotonin. Platelet derived vasoactive mediators may increase vascular permeability and facilitate further deposition of complexes in the tissues.
Introduction
Kawasaki disease, or the mucocutaneous lymph node syndrome, is an acute, feverish illness affecting young children, with prominent mucocutaneous and cardiovascular manifestations.' Since its description in 1967 many thousands of cases have been seen in Japan, and the disease is recognised increasingly often in many other countries. 23 Kawasaki disease is often a benign and self limited illness. Arteritis affecting the extraparenchymal muscular arteries is, however, common and results in the development of coronary artery aneurysms in 20-600o of cases.46 Death due to coronary artery thrombosis, myocardial infarction, or aneurysm rupture occurs in 1-2 80,, of patients in the first three months of the illness,2 4-6 and there are reports of sudden death due to myocardial infarction occurring months to years after the initial illness.
Coronary artery aneurysms and myocardial infarction are most commonly detected after the second week of the illness and usually occur at a time when the fever and mucocutaneous manifestations are subsiding and the child appears to be convalescing.8 Thrombocytosis also occurs at this time, with the platelet count often exceeding 1000 x 109/1.2 This puzzling temporal association of thrombocytosis with the development
